Published in Eur Respir Rev on September 01, 2011
Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res (2013) 1.86
Impact of night-time symptoms in COPD: a real-world study in five European countries. Int J Chron Obstruct Pulmon Dis (2013) 1.16
Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res (2014) 1.12
Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respir Res (2015) 1.11
Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study. Respir Res (2014) 1.10
Circadian clock function is disrupted by environmental tobacco/cigarette smoke, leading to lung inflammation and injury via a SIRT1-BMAL1 pathway. FASEB J (2013) 1.02
Symptom variability in COPD: a narrative review. Int J Chron Obstruct Pulmon Dis (2013) 0.95
Impact and factors associated with nighttime and early morning symptoms among patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2015) 0.93
The development of a patient-reported outcome measure for assessing nighttime symptoms of chronic obstructive pulmonary disease. Health Qual Life Outcomes (2013) 0.89
Serotonin and corticosterone rhythms in mice exposed to cigarette smoke and in patients with COPD: implication for COPD-associated neuropathogenesis. PLoS One (2014) 0.86
Associations between nighttime traffic noise and sleep: the Finnish public sector study. Environ Health Perspect (2012) 0.85
Circadian disruption alters mouse lung clock gene expression and lung mechanics. J Appl Physiol (1985) (2012) 0.84
Self-reported sleep quality and acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2015) 0.83
Evaluation of the psychometric properties of the Nighttime Symptoms of COPD Instrument. Int J Chron Obstruct Pulmon Dis (2015) 0.79
Systematic literature review of patient-reported outcome measures used in assessment and measurement of sleep disorders in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2015) 0.78
Pulmonary Overlap Syndromes, with a focus on COPD and ILD. Sleep Med Clin (2014) 0.78
Chronic obstructive pulmonary disease and obstructive sleep apnoea-the overlap syndrome. J Thorac Dis (2016) 0.77
The relationships among sleep efficiency, pulmonary functions, and quality of life in patients with asthma. Int J Gen Med (2014) 0.77
Chronic obstructive pulmonary disease phenotype desaturator with hypoxic vascular remodelling and pulmonary hypertension obtained by cluster analysis. Multidiscip Respir Med (2012) 0.77
Effects of aclidinium on determinants of COPD severity: symptoms and quality of life. Int J Chron Obstruct Pulmon Dis (2016) 0.77
Symptoms and quality of life in patients with chronic obstructive pulmonary disease treated with aclidinium in a real-life setting. Eur Clin Respir J (2016) 0.75
Morning and night symptoms in primary care COPD patients: a cross-sectional and longitudinal study. An UNLOCK study from the IPCRG. NPJ Prim Care Respir Med (2016) 0.75
Sleep complaints and sleep breathing disorders in upper and lower obstructive lung diseases. J Thorac Dis (2016) 0.75
Frequent sputum production is associated with disturbed night's rest and impaired sleep quality in patients with COPD. Sleep Breath (2015) 0.75
Transcriptome Profiling of the Lungs Reveals Molecular Clock Genes Expression Changes after Chronic Exposure to Ambient Air Particles. Int J Environ Res Public Health (2017) 0.75
Experience of insomnia, symptom attribution and treatment preferences in individuals with moderate to severe COPD: a qualitative study. Patient Prefer Adherence (2014) 0.75
Understanding the impact of symptoms on the burden of COPD. Respir Res (2017) 0.75
A cross-sectional survey of night-time symptoms and impact of sleep disturbance on symptoms and health status in patients with COPD. Int J Chron Obstruct Pulmon Dis (2017) 0.75
Airflow obstruction: is it asthma or is it COPD? Int J Chron Obstruct Pulmon Dis (2016) 0.75
Sleep in Chronic Obstructive Pulmonary Disease: Evidence Gaps and Challenges. Can Respir J (2016) 0.75
Factors responsible for poor sleep quality in patients with chronic obstructive pulmonary disease. BMC Pulm Med (2016) 0.75
Sex differences in reported and objectively measured sleep in COPD. Int J Chron Obstruct Pulmon Dis (2016) 0.75
Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies. NPJ Prim Care Respir Med (2017) 0.75
When is dual bronchodilation indicated in COPD? Int J Chron Obstruct Pulmon Dis (2017) 0.75
Umeclidinium in chronic obstructive pulmonary disease: latest evidence and place in therapy. Ther Adv Chronic Dis (2017) 0.75
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med (2011) 7.89
Mutations and prognosis in primary myelofibrosis. Leukemia (2013) 3.13
Daytime sleepiness and polysomnographic variables in sleep apnoea patients. Eur Respir J (2007) 2.61
Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia (2010) 2.30
Augmented resting sympathetic activity in awake patients with obstructive sleep apnea. Chest (1993) 2.24
Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia (2010) 2.23
Insulin resistance and daytime sleepiness in patients with sleep apnoea. Thorax (2008) 2.02
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia (2013) 1.97
Gamma glutamyl transferase and oxidative stress in obstructive sleep apnea: a study in 1744 patients. Sleep Breath (2015) 1.95
Guidelines for the use of recombinant human erythropoietin. Haematologica (1995) 1.94
Increased incidence of coronary artery disease in sleep apnoea: a long-term follow-up. Eur Respir J (2006) 1.93
The 6-min walk distance in healthy subjects: reference standards from seven countries. Eur Respir J (2010) 1.90
Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat. Pain (1992) 1.89
Snoring and sleep apnoea in men: association with central obesity and hypertension. Int J Obes Relat Metab Disord (1993) 1.82
Elastin fragments attract macrophage precursors to diseased sites in pulmonary emphysema. Science (1981) 1.80
Sex differences in mortality in patients with COPD. Eur Respir J (2008) 1.79
An independent association between obstructive sleep apnoea and coronary artery disease. Eur Respir J (1999) 1.78
Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J (2010) 1.78
Respiratory disturbance index: an independent predictor of mortality in coronary artery disease. Am J Respir Crit Care Med (2000) 1.76
Antioxidant status in patients with sleep apnoea and impact of continuous positive airway pressure treatment. Eur Respir J (2006) 1.70
Outdoor air pollution, climatic changes and allergic bronchial asthma. Eur Respir J (2002) 1.64
Impairment of vascular endothelial function and left ventricular filling : association with the severity of apnea-induced hypoxemia during sleep. Chest (2001) 1.59
Management of obstructive sleep apnea in Europe. Sleep Med (2010) 1.56
Comparison of atenolol, amlodipine, enalapril, hydrochlorothiazide, and losartan for antihypertensive treatment in patients with obstructive sleep apnea. Am J Respir Crit Care Med (2000) 1.54
Intravenous iron therapy for severe anaemia in systemic-onset juvenile chronic arthritis. Lancet (1994) 1.52
Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. Leukemia (2010) 1.51
Inhaled salmeterol and salbutamol in asthmatic patients. An evaluation of asthma symptoms and the possible development of tachyphylaxis. Am Rev Respir Dis (1990) 1.50
Impact of non-linear smoking effects on the identification of gene-by-smoking interactions in COPD genetics studies. Thorax (2010) 1.46
Energy expenditure in obstructive sleep apnea: effects of treatment with continuous positive airway pressure. Am J Physiol (1996) 1.45
Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. Leukemia (2006) 1.45
Effectiveness of continuous positive airway pressure in mild sleep apnea-hypopnea syndrome. Am J Respir Crit Care Med (2001) 1.43
COPD exacerbations: the importance of a standard definition. Respir Med (2004) 1.42
Low value of adenosine deaminase in tuberculous pleural effusions. Eur Respir J (1990) 1.39
Inhibin as a marker for hydatidiform mole: a comparative study with the determinations of intact human chorionic gonadotrophin and its free beta-subunit. Clin Endocrinol (Oxf) (1994) 1.38
[The results of the operation of a monitoring unit for home oxygen therapy]. Arch Bronconeumol (1999) 1.38
Patients with obstructive sleep apnea exhibit genioglossus dysfunction that is normalized after treatment with continuous positive airway pressure. Am J Respir Crit Care Med (1999) 1.37
Therapeutic electrical stimulation of the hypoglossal nerve in obstructive sleep apnea. Arch Otolaryngol Head Neck Surg (2001) 1.32
Quantitative evaluation of erythropoietic activity in dysmyelopoietic syndromes. Br J Haematol (1982) 1.27
Impact of obstructive sleep apnea and sleepiness on metabolic and cardiovascular risk factors in the Swedish Obese Subjects (SOS) Study. Int J Obes Relat Metab Disord (1995) 1.22
Adenosine mechanisms in the regulation of breathing in the rat. Eur J Pharmacol (1984) 1.20
Unbalanced X-chromosome inactivation in haemopoietic cells from normal women. Br J Haematol (1998) 1.20
Evidence for a polyclonal nature of the cell infiltrate in sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). Br J Haematol (1995) 1.19
Abnormal lipid peroxidation in patients with sleep apnoea. Eur Respir J (2000) 1.19
Therapy with nCPAP: incomplete elimination of Sleep Related Breathing Disorder. Eur Respir J (2000) 1.18
Changes in obstructive sleep apnea characteristics through the night. Chest (1994) 1.17
Antinociceptive and ventilatory effects of the morphine metabolites: morphine-6-glucuronide and morphine-3-glucuronide. Eur J Pharmacol (1991) 1.16
Synthesis of fibronectin, laminin, and several collagens by a liver-derived epithelial line. Lab Invest (1980) 1.16
A linkage between hereditary hyperferritinaemia not related to iron overload and autosomal dominant congenital cataract. Br J Haematol (1995) 1.15
The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. Leukemia (2009) 1.15
The dysmetabolic iron overload syndrome is clinically and genetically distinct from HFE-related genetic hemochromatosis. Haematologica (1999) 1.14
Appendico-cutaneous fistula. A case report. Acta Chir Scand (1978) 1.12
Long-term effects of CPAP on daytime functioning in patients with sleep apnoea syndrome. Eur Respir J (2000) 1.12
The European Sleep Apnoea Database (ESADA): report from 22 European sleep laboratories. Eur Respir J (2011) 1.11
Nitrazepam in patients with sleep apnoea: a double-blind placebo-controlled study. Eur Respir J (1994) 1.10
Acetaminophen blocks spinal hyperalgesia induced by NMDA and substance P. Pain (1994) 1.09
Differential HFE allele expression in hemochromatosis heterozygotes. Gastroenterology (2001) 1.09
Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome. Leukemia (2005) 1.09
Effects of diesel exhaust particles on human lung epithelial cells: an in vitro study. Respir Med (2007) 1.09
The 6-min walking distance: long-term follow up in patients with COPD. Eur Respir J (2006) 1.09
Sleep-related breathing disorder is an independent risk factor for uncontrolled hypertension. J Hypertens (2000) 1.09
Clinical severity and thermodynamic effects of iron-responsive element mutations in hereditary hyperferritinemia-cataract syndrome. J Biol Chem (1999) 1.08
Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD. Chest (2001) 1.07
Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol (1998) 1.06
The effects of nasal dilation on snoring and obstructive sleep apnea. Arch Otolaryngol Head Neck Surg (1992) 1.06
IFN-alpha treatment enhances porcine Arterivirus infection of monocytes via upregulation of the porcine Arterivirus receptor sialoadhesin. J Interferon Cytokine Res (2007) 1.04
Clinical, laboratory and radiographic features in early rheumatoid arthritis. J Rheumatol (1990) 1.03
Smoking cessation is associated with an increase in exhaled nitric oxide. Chest (1997) 1.03
Blood pressure, cardiac structure and severity of obstructive sleep apnea in a sleep clinic population. J Hypertens (2001) 1.02
Effects of obesity upon genioglossus structure and function in obstructive sleep apnoea. Eur Respir J (2004) 1.02
Transferrin saturation, plasma iron turnover, and transferrin uptake in normal humans. Blood (1985) 1.01
Leukemia risk models in primary myelofibrosis: an International Working Group study. Leukemia (2012) 1.01
Biologic and clinical significance of red cell ferritin. Blood (1983) 1.00
The role of outdoor air pollution and climatic changes on the rising trends in respiratory allergy. Respir Med (2001) 1.00
Spontaneous disappearance of Elschnig pearls after neodymium:YAG laser posterior capsulotomy. J Cataract Refract Surg (1997) 1.00
Natural evolution of Elschnig pearl posterior capsule opacification after posterior capsulotomy. J Cataract Refract Surg (2001) 0.99
Mechanisms of neutrophil recruitment to the lung by grain dust exposure. Am Rev Respir Dis (1988) 0.99
The modified BODE index: validation with mortality in COPD. Eur Respir J (2008) 0.99
Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur Respir J (2003) 0.99
Atrial peptides, ANP(1-98) and ANP(99-126) in health and disease in an elderly population. Eur Heart J (1993) 0.99
Juvenile hemochromatosis locus maps to chromosome 1q. Am J Hum Genet (1999) 0.98
Reduced hospitalization with cardiovascular and pulmonary disease in obstructive sleep apnea patients on nasal CPAP treatment. Sleep (1997) 0.98
Saporin, a ribosome-inactivating protein used to prepare immunotoxins, induces cell death via apoptosis. Br J Haematol (1996) 0.98
Regulation of breathing in the rat: indications for a role of central adenosine mechanisms. Neurosci Lett (1982) 0.97
Myelodysplastic syndromes: recent advances. Haematologica (2001) 0.97
Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids. Respir Med (2012) 0.95
Free fatty acids and the metabolic syndrome in patients with obstructive sleep apnoea. Eur Respir J (2010) 0.95
Effect of an ambulatory diagnostic and treatment programme in patients with sleep apnoea. Eur Respir J (2011) 0.94
Effect of serotonin uptake inhibition on breathing during sleep and daytime symptoms in obstructive sleep apnea. Sleep (1999) 0.94
Juvenile idiopathic haemochromatosis: a life-threatening disorder presenting as hypogonadotropic hypogonadism. Hum Genet (1983) 0.94
Alternative mechanisms for tiotropium. Pulm Pharmacol Ther (2009) 0.94
Apoptosis: biological and clinical aspects. Haematologica (2004) 0.94
Iron loading in congenital dyserythropoietic anaemias and congenital sideroblastic anaemias. Br J Haematol (1983) 0.93
The neuropharmacology of respiratory control. Pharmacol Rev (1982) 0.93
Central, naloxone-reversible antinociception by diclofenac in the rat. Naunyn Schmiedebergs Arch Pharmacol (1990) 0.92
Occurrence and correlates of sleep disordered breathing in the Australian town of Busselton: a preliminary analysis. Sleep (1993) 0.92
CD34-positive cells: biology and clinical relevance. Haematologica (1995) 0.92
Reduced alpha- and beta(2)-adrenergic vascular response in patients with obstructive sleep apnea. Am J Respir Crit Care Med (2000) 0.92